ReShape Lifesciences (RSLS)

Take Impact Assessment

Impact Scorecard
About

Overall impact

B (64)

Commentary

ReShape Lifesciences is a strong overall performer. With a 'B' rating of 64.4 for overall impact (72nd percentile compared to all companies), ReShape Lifesciences ranks 55th out of 103 industry peers, behind Waters, MyMD Pharmaceuticals, Alphatec and 51 others, and ahead of Tandem Diabetes Care, InMode, Envista Holdings and 45 others. On top material causes for ReShape Lifesciences's industry (Healthcare Equipment), ReShape Lifesciences performs well in Humane Treatment of Animals (80.9 score), Conflict Free Mineral Production (96.0), Reduced Waste (88.1) and 4 other causes where it received an 'A' score and performs poorly in Technology Innovation (15.6 score) and Reduced Green House Gas Emissions (26.6).

... read full commentary

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact

Cause			RSLS

Peer rank

Overall impact

Log in to view this information

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Employees

Sector

Health Care

Industry

Health Care Equipment & Supplies

Sub-industry

Health Care Supplies

SASB industry

Medical Equipment & Supplies

Headquarters

Ca, United States

Share classes

RSLS

More info

https://www.reshapelifesciences.com

Description

ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes the Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; the Lap-Band 2.0 System, which is adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, which fit the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in Irvine, California.

Material causes

Ethos considers the following causes material for ReShape Lifesciences, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

Access to affordable healthcare

Ensure universal access to affordable, quality healthcare

Accountable institutions

Build accountable and inclusive institutions at all levels

Child and maternal health

End preventable deaths of mothers and children, support reproductive health everywhere

Conflict-free mineral production

Reduce violence in the production of minerals

Decent, safe work opportunities

Promote full and productive employment for all, in safe work environments

Disaster readiness and effective aid

Be prepared for natural disasters and provide effective aid when disasters happen